Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors

Annals of Oncology

Volumn 9, Issue 7, 1998, Pages 733-738

  Rothenberg, M L ^a,b,e   Sharma, A ^a   Weiss, G R ^a,b   Villalona Calero, M A ^b   Eckardt, J R ^a,b   Aylesworth, C ^c   Kraynak, M A ^a,b   Rinaldi, D A ^c   Rodriguez, G I ^a,b   Burris III, H A ^b,c   Eckhardt, S G ^b   Stephens, C D ^b   Forral, K ^b   Nicol, S J ^d   Von Hoff, D D ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

^c BROOKE ARMY MEDICAL CENTER   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Gemcitabine; Paclitaxel; Phase I

Indexed keywords

GEMCITABINE; PACLITAXEL;

ADENOCARCINOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; HUMAN; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; TRANSITIONAL CELL CARCINOMA;

EID: 7344264012     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008286908930     Document Type: Article

References (19)

1. Grindey GB, Hertel LW, Plunkett W. Cytotoxicity and antitumor activity of 2′,2′-difluorodeoxycytidine (Gemcitabine). Cancer Invest 1990; 8: 313-8.
2. Hertel LW, Bodel GB, Kroin JS et al. Evaluation of the antitumor activity of gemcitabine (2,2-difluoro-2-deoxycytidine). Cancer Res 1990; 50: 4417-22.
3. Huang P, Chubb S, Hertl LW et al. Action of 2′,2′- difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51: 6110-7.
4. Noble S, Goa KL. Gemcitabine: A review of its phamacology and clinical potential in non-small-cell lung cancer and pancreatic cancer. Drugs 1997; 54: 447-72.
5. Guchelaar H-J, Richel DL, van Knapen A. Clinical. toxicological, and pharmacological aspects of gemcitabine. Cancer Treat Rev 1996; 22: 15-31.
6. Peters GJ, Bergman AM, Ruiz van Haperen VW et al. Interaction between cisplatin and gemcitabine in vitro and in viro. Semin Oncol 1995;22(4 Suppl II): 72-9.
7. Peters GJ, van Haperen VWT, Bergman AM et al. Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol 1996; 23: 16-24.
8. Jensen PB, Holm B, Sorensen M et al. In vitro cross resistance and collateral sensitivity in seven resistant small-cell-lung cancer cell lines: Preclinical identification of suitable drug partners toTaxotere. topotecan and gemcitabine. Br J Cancer 1997; 75: 869-77.
9. Gazitt Y, Rothenberg M, Fey V et al. Gemcitabine is a pancytotoxic drug for various multiple myeloma cell lines, whereas Taxol cyctotoxicity is dependent on the expression of bcl-2. Blood 1997; 90 (Suppl I): 326a (Abstr 1455).
10. Curtis JE, Minkin S, Minden MD, McCulloch EA. A role for paclitaxel in the combination chemotherapy of acute myeloblastic leukemia: Preclinical cell culture studies. Br J Hematol 1996; 95: 354-63.
11. Rowinsky EK, Donehower RC, Paclitaxel (Taxol). N Engl J Med 1995; 332: 1004-14.
12. Brown T, O'Rourke T, Burris H et al. A phase I trial of gemcitabine (LY 188011) administered intravenously every two weeks. Proc Am Soc Clin Oncol 1991; 10: 115 (Abstr 328).
13. Tanis B, Clavel M, Guastalla J et al. Phase I study of gemcitabine (difluorodeoxycytidine; dFdC; LY 188011) administered in a two-weekly schedule. Proc Am Assoc Cancer Res 1990; 31: 207 (Abstr 1230).
14. Tolcher AW. Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer. Semin Oncol 1996; 23 (Suppl I): 37-43.
15. Poole CJ, Cook J, Hogberg T et al. A phase I clinical trial of gemcitabine and paclitaxel in patents with recurrent epithelial ovarian cancer. Ann Oncol 1996; 7 (Suppl 5): 72 (Abstr 341P).
16. Georgoulias V, Kourousis C, Kakolyris S et al. Second-line treatment of advanced non-small-cell lung cancer with paclitaxel and gemcitabine: A preliminary report on an active regimen. Semin Oncol 1997; 24 (Suppl 12): S12-61-S12-66.
17. Stadler WM, Kuzel T, Roth B et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997; 15: 3394-8.
18. Moore MJ, Tannock I, Ernst S et al. Gemcitabine demonstrates promising activity as a single agent in the treatment of metastatic transitional cell carcinoma. Proc Am Soc Clin Oncol 1996; 15: 250 (Abstr 637).
19. Roth BJ, Dreicer R, Einhorn LH, Neuberg D et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. J Gin Oncol 1994; 12: 2264-70.